97 results
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc
2 May 24
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
6:03am
erythematosus (SLE), a chronic and complex autoimmune disease. LN affects approximately 120,000 people in the U.S. and disproportionately affects women
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc
15 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
6:06am
with active LN without reliance on chronic high-dose glucocorticoids. It is the only clinical program to include three years of LN treatment and follow-up … (SLE), a chronic and complex autoimmune disease. LN affects approximately 120,000 people in the U.S. and disproportionately affects women and people
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc
5 Jan 24
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2023 Net Revenue Results
6:02am
in the fourth quarter since they have achieved numerical significance for the first time.
About Lupus Nephritis
LN is a serious manifestation of SLE, a chronic
8-K
EX-99.1
v26wdkks
2 Nov 23
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
6:01am
8-K
EX-99.1
io6ohmjax
3 Aug 23
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
6:03am
8-K
EX-99.1
tqd4 9s55
4 May 23
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
6:06am
8-K
EX-99.2
o6ak0n9uxh
5 Apr 23
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
8:16am
8-K
EX-99.1
wbsotlre17x4ne9vwo48
5 Apr 23
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
8:16am
8-K
EX-99.1
8nlkjpq23kkufq9 62j4
3 Nov 22
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
6:04am
8-K
EX-99.1
53hcoo3z0cfv3jysi
4 Aug 22
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
6:07am
8-K
EX-99.1
a9jh wgjh37z81chyie
10 May 22
Aurinia Reports First Quarter 2022 Financial and Operational Results
6:06am
8-K
EX-99.1
g8a5mzobr00trb2fz7id
28 Feb 22
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates
6:08am
8-K/A
EX-99.1
ihttn 9om28gwc
7 Jan 22
CLINICAL PROGRAM UPDATE AURORA 2 / voclosporin Updated January 2022
4:10pm
8-K
EX-99.1
s0m4uf1fdz5hka6r8x6
9 Dec 21
Regulation FD Disclosure
6:31am
8-K
EX-99.1
6s5m tnfw
3 Nov 21
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
12:00am